Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
going to add this DIP!!!
This is a overreaction IMO..
Only 5.29 million shares. Should have minimal effect on SP
Gonna be a bumpy ride today, but remember what you own
I think 9.80s was it here. When people panic sell after hours on low floaters the sell off is always more severe than it would be during hours.
$PDSB
my pick is $8.44..but hope it does not go that low..
So tomorrow we play catch a falling knife
We should hold a contest, "pick bottom"
It is actually a good call by management at these prices. Many companies would have done 3-4 by now if being predatory.
Well lets hope they announce the size and price pretty quick, certainly has been plenty of demand for the stock.
Maybe the offering pricing will be above current market
Kind of odd that someone bought so many shares EOD...
Like someone knew something... and then this offering ?
PDS Biotech Announces Proposed Offering of Common Stock
FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock to be sold in the offering will be offered by PDS Biotech. PDS Biotech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.
PDS Biotech intends to use a portion of the net proceeds from this offering for the development of our clinical pipeline and for general corporate purposes including working capital.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and became effective on July 31, 2020. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, NY 10022, Attn: Capital Markets Department, or by email at prospectus@cantor.com.
$PDSB
Nice volume here EOD... $PDSB...
Also Fress I have some free money , so if you have a good fresh pick beside $PDSB please drop me a PM
Wow somebody wanted in very quickly.
Release the kraken Franky baby!
Destroy Shortie!
PDSB JUNE 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/june/PDSB_Corporate_Overview_-_June_7_FINAL_1.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
https://giphy.com/gifs/animation-kraken-soDqW21ZbC1oc
$PDSB
Back to 52w highs!!!
Go $PDSB $15 next
This tiger is napping will wake up soon.
$PDSB
Copy that make sure you guys enjoy your Sunday I’m at the beach getting some rays listening to the waves crash and watching my girlfriend engaging in a yoga class!
$PDSB
Shorty should be getting nervous.
Where is everybody Have a great weekend folks!
Frank is just getting started. The man has a drawerful of cards to play. This is his baby, from the beginning, and he's got it all mapped out. When you bet on little pre-clinical and clinical stage biotechs in the very earlygoing, look at breadth & depth of potential of the pipeline, with a kickass platform.
$PDSB
Wealth Creator!
Happy Thursday Ladies & Gentlemen!
This stock defies gravity & is one of the best performing stocks in the last 12 months! Great board to be apart of!
The very strong upward trend continues, and will do so for quite a long while to come...
$PDSB
winner winner chicken dinner sit back and enjoy the show and watch your money grow.
PDSB JUNE 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/june/PDSB_Corporate_Overview_-_June_7_FINAL_1.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
TheFly.com
Portfolio Alerts
Click the Portfolio Name or Symbol to see the research on thefly.com
Main Portfolio matches: PDSB.
TODAY, JUNE 09, 2021
PDSB
07:05
Recommendations
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.
Oppenheimer- we raise our price target to $25 from $12. ASCO data flesh out compelling efficacy; PDSB to host virtual oncology R&D event on June 16th.
Lol, just saw this after I posted
Back to normal trading again I think. A lot of flippers out now
They will regret, thanks for the shares @ $9 yesterday...
They will regret, thanks for the shares @ $9 yesterday...
Looks like flippers who bought yesterday are getting out.
FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by PDS Biotechnology Corporation (Nasdaq: PDSB), we've been informed by the company, the beginning of the conference call paragraph should read "The company is hosting a conference call today at 8:00 am ET to discuss the data presented at ASCO." instead of "The company is hosting a conference call tomorrow morning at 8:00 am ET to discuss the data presented at ASCO."
Your welcome Diamond Hands Lasers Eyes!
PDSB May 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/may/PDSB_Corporate_Overview_-_May_24_2021_v5.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
$PDSB
Diamond hands.. Again I´m so happy for your tip back in February.
Please PM me next time you have a new tip.
I will help support it 100% like I am doing with $PDSB!!!
Hi bears lol lmao.
https://i.pinimg.com/originals/58/80/ef/5880ef672981142ff41ded2c0c25782c.gif
$PDSB
Nice recovery after a 200% move up in a few weeks! Anyone who talks this stock down needs help one of the best performers small cap bios in the market.
120k shares Long & Strong
$PDSB
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021...
June 08 2021 - 06:00AM
GlobeNewswire Inc.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute (NCI), of the National Institutes of Health (NIH), at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
The Phase 2 trial (NCT04287868) studies PDS0101 (Versamune®-HPV16) in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824), a bifunctional “trap” fusion protein targeting TGF-ß and PD-L1, and NHS-IL12 (M9241), a tumor-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16 (HPV16-positive cancers) by activating the immune system to produce in vivo CD8+ (killer) T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing.
Highlights from the presentation include the following:
Data from a total of 25 patients with data available as of the time of presentation submission:
Update on the data previously reported for the original fourteen (14) HPV16-positive patients who were in the subject of the abstract published on May 19th.
An additional seven (7) HPV16-negative patients (patients whose cancer was NOT caused by HPV16 infection) who were not discussed in the abstract.
An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.
100% (25/25) of patients enrolled had failed chemotherapy treatment.
96% (24/25) of patients enrolled had failed both chemotherapy and radiation treatment.
56% (14/25) of patients enrolled had failed checkpoint inhibitor therapy (checkpoint inhibitor refractory).
Most types of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) were represented among the study subjects.
The following update was provided on the initial six (6) HPV16-positive patients who had NOT been treated with checkpoint inhibitors (checkpoint inhibitor naïve):
83% (5/6) of the patients demonstrated an objective response (tumor reduction >30%). The reported objective response rate with current standard of care checkpoint inhibitor treatment is 12-24%.
100% (6/6) are still alive at 8 months – the historic average (median) survival or life span for this patient population is 7-11 months.
80% (4/5) of patients who had an objective response still have an ongoing response at 8 months.
One (1) patient had a complete response (no evidence of disease).
No new patients had been added to this group by the time of submission.
The following information was provided on the twelve (12) HPV16-positive patients who have also failed treatment with checkpoint inhibitors after failing chemotherapy and radiation treatment (checkpoint inhibitor refractory):
Four patients had recently been added since the abstract. Tumor reduction was observed in 58% (7/12), with an overall objective response rate of 42% (5/12) already achieved; the objective response rate of the current standard of care is 5-12%
One patient in this group had achieved a complete response by the time of reporting
80% (4/5) of patients who had an objective response have an ongoing response at 8 months
83% (10/12) of patients are still alive at 8 months; historic average (median) survival or life span for this patient population is only 3-4 months
PDS0101 is designed to treat patients whose cancer is caused by infection with HPV16. Seven (7) patients had cancer that was not caused by HPV16 (HPV16-negative patients). In this group
0% (0/7) experienced tumor reduction.
80% (4/5) checkpoint inhibitor naïve patients are still alive at 8 months.
0% (0/2) checkpoint inhibitor refractory patients are still alive at 8 months.
https://ih.advfn.com/stock-market/NASDAQ/pds-biotechnology-PDSB/stock-news/85307273/pds-biotech-announces-release-of-interim-data-for
The pullback was right on the money. about 60%
If you look at PPBT last Friday did same thing. They had an oral presentation at 7:am that day and it sold off 60% then turned. I was going to set up at 8.40 to buy but passed thinking it wouldn't happen with PDS
877-407-3088 is the number to listen in as frank reviews the Results on Tuesday 6/8 at 8:am
$PDSB - 10.74 in AHs trading.. Nice comeback..
RSI down to 55 now. Thats nice going into tomorrow
Very nice run up from the $4-$5 range. Congrats to the longs!
This one seems to have a hard pull back whenever there is a run up on news. The kicker is knowing when to sell if you want to take some profit, before the pullback.
Sold some, but still holding with average of $4.52....
GLTA
was able to accumulate 5K shares at an avg of 8.6.. Never expected it will have a nice pullback like this..
Hi Fress, glad to hear from you and see that you are still here.
I added some @ $9 today aswell.
Today consolidation was needed due to quick move.
$PDSB
from pharmD on twitter
$PDSB
For a second try to digest how important this data is for R/R advanced HPV malignancies.
1) 1st line Chemo and or Radiation Tx, if fails followed by CI therapy.
2) ORR is about 12-24% with Checkpoint Inhibitors for R/R cancer that doesn’t respond to chemo/radiation tx.
3) BintraFusp alfa highest ORR so far close to 30% who are CI naive.
4) BintraFusp alfa showed ORR close to 10% in advanced HPV refractory to CI therapy.
5) Now PDS0101 triplet therapy shows an ORR of 10/14 (71%). Not sure why some biotech analysts ignoring this data
Added 22k shares at 8.34-8.42 average. 50% FIB RESET after a $200% move from low 4.00s to 13.00 Plus in two weeks was needed nice reset. Don't hate the player hate the game.
122k Shares long and down payment on a vacation home in Maui in since the lows of the year. Thank you PDSB
Biotechs heating up across the board.
$PDSB
$PDSB Consolidation was needed.
We will be back in double digits and test new 52w high.
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1582
|
Created
|
06/17/20
|
Type
|
Free
|
Moderators |
https://pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf |
DEVELOPING POWERFUL, SAFE, VERSATILE IMMUNOTHERAPIES |
PDSB Versamune® T cell Platform. Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum. |
PDSB analyst coverage: |
SECOND GENERATION COVID-19 VACCINE PHASE 3 Q4 2021 PDSB $100.00 PRICE PER SHARE =2.2 BILLION MARKET CAP |
PDSB biz presentation 2021: PDSB White Paper: https://pdsbiotech.com/images/pdf/presentation/2021/Whitepaper-2021_v6.pdf PDSB Biotech preparing to initiate 3 CANCER Phase 2 clinical studies for lead candidate PDS0101: https://www.youtube.com/watch?v=iYZRmRmRtUI&t=2s OPPENHEIMER Annual Healthcare Conference MARCH 16TH 2021 https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=pdsb&url=https://wsw.com/webcast/oppenheimer9/pdsb/2708189 PDSB website: |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |